Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Pharm Res ; 37(5): 90, 2020 May 07.
Article in English | MEDLINE | ID: mdl-32382838

ABSTRACT

PURPOSE: The blood-brain barrier limits the application of idarubicin in the therapy of glioblastoma multiforme. Biodegradable, intracranial wafers with prolonged release may increase therapy efficiency. METHODS: Blank wafers, wafers containing 5% w/w and 10% w/w of idarubicin were formulated by solution casting from poly(L-lactide-co-glycolide) and poly(glycolide-co-ε-caprolactone). The following methods were used: NMR, GPC, DSC, FTIR, AFM, UV-VIS, and a viability and proliferation assay for idarubicin action (U87MG cell line). RESULTS: Wafers showed a surface with numerous immersions and hills. A lack of interactions between idarubicin and the copolymers was observed. The substance was entrapped in the matrix and released in two phases for all wafers with the appropriate bolus and maintenance dose. The burst effect was observed for all wafers, however, the biggest bolus for poly(L-lactide-co-glycolide) wafers containing 5% w/w of idarubicin was noted. The stable and steady degradation of poly(glycolide-co-ε-caprolactone) wafers containing 5% w/w of idarubicin ensures the most optimal release profile and high inhibition of proliferation. CONCLUSIONS: Copolymer wafers with idarubicin are an interesting proposition with great potential for the local treatment of glioblastoma multiforme. The release rate and dose may be regulated by the amount and kind of wafers for various effects.


Subject(s)
Drug Carriers/chemical synthesis , Glioblastoma/drug therapy , Idarubicin/therapeutic use , Polymers/chemical synthesis , Cell Line, Tumor , Cell Survival , Drug Liberation , Humans , Polylactic Acid-Polyglycolic Acid Copolymer , Technology, Pharmaceutical/methods
2.
Postepy Hig Med Dosw (Online) ; 59: 75-81, 2005 Mar 17.
Article in Polish | MEDLINE | ID: mdl-15928590

ABSTRACT

The adduction of the aldehydic end-products of lipid peroxidation to DNA induces bulky adducts, leading to genome instability. The bulky-DNA adducts are miscoding and thus play a fundamental role in mutagenesis and cancerogenesis. Special attention is given to the etheno- and propanoadducts, recognized as DNA modifiers. Such DNA lesions are repaired by different DNA repair mechanisms, mainly base excision repair (BER) and nucleotide excision repair (NER), as well as nucleotide incision repair (NIR) and transcription-coupled repair (TCR).


Subject(s)
DNA Damage/physiology , DNA Repair , Lipid Peroxidation/physiology , Animals , DNA Adducts/physiology , Free Radicals/metabolism , Gene Expression Regulation, Neoplastic/genetics , Humans , Mutagenesis/genetics , Reactive Oxygen Species/metabolism , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...